Mattia Alberto Di Civita
Overview
Explore the profile of Mattia Alberto Di Civita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roberto M, Di Civita M, Marinelli D, Torchia A, Cara N, Maltese G, et al.
BJUI Compass
. 2025 Jan;
6(1):e455.
PMID: 39877569
Background: We present a systematic review and meta-analysis of randomized clinical trials (RCTs) with PARPi either as monotherapy or in combination with an androgen receptor-targeted agent (ARTA) in first- and...
2.
Salciccia S, Santarelli V, Di Pierro G, Del Giudice F, Bevilacqua G, Di Lascio G, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518044
: The advantage of a robotic-assisted (RARP) over a laparoscopic (LRP) approach in radical prostatectomy (RP) remains to be demonstrated. : The aim of the study is to use a...
3.
Santini D, Li H, Roviello G, Park S, Grande E, Kucharz J, et al.
Target Oncol
. 2024 Sep;
19(6):893-903.
PMID: 39289313
Background: Therapeutic advancements based on immuno-oncology combinations have revolutionized the management of patients with renal cell carcinoma. However, patients who have progressive disease as the best response, "primary refractory" (P),...
4.
Di Civita M, Torchia A, Santini D, Marinelli D, Magro V, Cerro M, et al.
Curr Oncol
. 2024 Aug;
31(8):4713-4727.
PMID: 39195335
Introduction: Platinum-based chemotherapy represents the standard of care (SoC) for the first-line treatment of advanced urothelial carcinoma (mUC). The benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy was...
5.
Santamaria F, Roberto M, Buccilli D, Di Civita M, Giancontieri P, Maltese G, et al.
Crit Rev Oncol Hematol
. 2024 Jun;
200:104405.
PMID: 38838928
In the last two-decades, innovative drugs have revolutionized cancer treatments, demonstrating a significant improvement in overall survival. These drugs may present several pharmacokinetics interactions with non-oncological drugs, and vice versa,...
6.
Marinelli D, Gallina F, Pannunzio S, Di Civita M, Torchia A, Giusti R, et al.
Crit Rev Oncol Hematol
. 2023 Oct;
192:104190.
PMID: 37871779
The use of neoadjuvant or perioperative anti-PD(L)1 was recently tested in multiple clinical trials. We performed a systematic review and meta-analysis of randomised trials comparing neoadjuvant or perioperative chemoimmunotherapy to...
7.
Carconi C, Cerreti M, Roberto M, Arrivi G, DAmbrosio G, De Felice F, et al.
Crit Rev Oncol Hematol
. 2023 Apr;
186:103990.
PMID: 37061075
Oligometastatic disease has been described as an intermediate clinical state between localized cancer and systemically metastasized disease. Recent clinical studies have shown prolonged survival when aggressive locoregional approaches are added...
8.
Roberto M, Arrivi G, Di Civita M, Barchiesi G, Pilozzi E, Marchetti P, et al.
Front Oncol
. 2023 Apr;
13:1154581.
PMID: 37035150
Introduction: Chemokines are small, secreted peptides involved in the mediation of the immune cell recruitment. Chemokines have been implicated in several diseases including autoimmune diseases, viral infections and also played...